MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)
MeiraGTx Holdings plc Ordinary Shares · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $9.80
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS